Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Challenges in conducting paediatric trials with off-patent drugs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Medication errors in residential facilities based on Danish Poison Information Center inquiries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Male fertility before and after androgen abuse

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • INDICES consortium
Vis graf over relationer

Carboxylesterase 1 (CES1) metabolizes methylphenidate and other drugs. CES1 gene variation only partially explains pharmacokinetic (PK) variability. Biomarkers predicting the PKs of drugs metabolized by CES1 are needed. We identified lipids in plasma from 44 healthy subjects that correlated with CES1 activity as determined by PK parameters of methylphenidate including a ceramide (q value = 0.001) and a phosphatidylcholine (q value = 0.005). Carriers of the CES1 143E allele had decreased methylphenidate metabolism and altered concentration of this phosphatidylcholine (q value = 0.040) and several high polyunsaturated fatty acid lipids (PUFAs). The half-maximal inhibitory concentration (IC50 ) values of chenodeoxycholate and taurocholate were 13.55 and 19.51 μM, respectively, consistent with a physiological significance. In silico analysis suggested that bile acid inhibition of CES1 involved both binding to the active and superficial sites of the enzyme. We initiated identification of metabolites predicting PKs of drugs metabolized by CES1 and suggest lipids to regulate or be regulated by this enzyme.

OriginalsprogEngelsk
TidsskriftCPT: pharmacometrics & systems pharmacology
Vol/bind7
Udgave nummer8
Sider (fra-til)525-533
Antal sider9
ISSN2163-8306
DOI
StatusUdgivet - aug. 2018

ID: 55270223